Pulling SEC filings + quote and writing the call…
TWST
Twist Bioscience Corp
Next earnings Aug 3, 2026 · consensus $-0.51 EPS, $117M rev
Last earnings -7.0% on 2026-05-04
$86.55
▲ +1.62%$85.17▲ +143.07%
over 1Y
L $24.16EODHDH $87.56
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.6%
1W+5.4%
1M+31.3%
3M+91.4%
YTD+163.0%
1Y+143.1%
Hold
Conviction
Horizon
Long (>12mo)
Street · 15 analysts
Strong Buy
Synthetic-DNA leader growing 20% with losses shrinking fast toward breakeven — encouraging, but 14x sales still bakes in a lot.
Twist Bioscience is the leading provider of synthetic DNA manufactured on a proprietary silicon-chip platform, selling into NGS tools, synthetic biology and biopharma. The FY2025 trajectory is the encouraging part of the story: revenue grew 20.3% to $377M, and the bottom line improved dramatically — the net loss narrowed to -$77.7M from -$209M (a 62.8% improvement), the operating loss shrank to -$136M, and operating cash burn fell to -$47.6M (a 25.7% improvement). The company is clearly executing on a path from growth-at-all-costs toward operating leverage, even trimming R&D 11.6% to $80.3M while still growing the top line.
Sources: SEC EDGAR (CIK 0001581280, latest 10-Q filed 2026-05-04) · EODHD · analysis by claude-code · as of 6/21/2026, 9:00:30 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.